Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.180
+0.170 (8.46%)
Nov 21, 2024, 4:00 PM EST - Market closed
Taysha Gene Therapies Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 21, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 447 | 331 | 141 | 448 | 1,002 | - |
| Market Cap Growth | -30.27% | 134.50% | -68.52% | -55.28% | - | - |
| Enterprise Value | 317 | 227 | 170 | 314 | 724 | - |
| Last Close Price | 2.01 | 1.77 | 2.26 | 11.65 | 26.54 | - |
| PS Ratio | 47.78 | 21.42 | 56.40 | - | - | - |
| PB Ratio | 4.64 | 4.42 | 148.70 | 4.70 | 3.99 | - |
| P/TBV Ratio | 4.64 | 4.42 | 148.70 | 4.70 | 3.99 | - |
| EV/Sales Ratio | 32.00 | 14.67 | 67.98 | - | - | - |
| Debt / Equity Ratio | 0.71 | 0.83 | 63.15 | 0.66 | - | - |
| Asset Turnover | 0.05 | 0.10 | 0.01 | - | - | - |
| Quick Ratio | 5.38 | 3.92 | 1.40 | 2.88 | 35.24 | - |
| Current Ratio | 5.51 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 |
| Return on Equity (ROE) | -114.77% | -294.04% | -344.67% | -100.68% | -47.79% | - |
| Return on Assets (ROA) | -27.42% | -29.84% | -46.30% | -45.81% | -20.76% | - |
| Return on Capital (ROIC) | -63.36% | -45.13% | -71.82% | -52.85% | -21.40% | - |
| Earnings Yield | -5.53% | -33.71% | -117.64% | -38.94% | -5.99% | - |
| FCF Yield | -19.28% | -23.23% | -77.25% | -29.53% | -3.07% | - |
| Buyback Yield / Dilution | -203.71% | -164.20% | -16.74% | -113.13% | -83.53% | - |
| Total Shareholder Return | -203.71% | -164.20% | -16.74% | -113.13% | -83.53% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.